CalciMedica, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CALC research report →
Range $14 – $392
Price Chart
About the company
CalciMedica, Inc. , a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions.
- CEO
- A. Rachel Leheny
- IPO
- 2023
- Employees
- 15
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on CALC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.97M
- P/E
- -0.28
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 2.06
- EV/EBITDA
- 0.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -3029.57%
- ROIC
- -164.16%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-23,121,000
- Net Income
- $-29,562,000-115.8%
- EPS
- $-9.85-61.5%
- OCF Growth
- -0.2%
- FCF Growth
- -0.2%
- 52W High
- $36.00
- 52W Low
- $1.00
- 50D MA
- $1.44
- 200D MA
- $2.92
- Beta
- 1.10
- RSI (14)
- 46
- Avg Volume
- 80.15K
No earnings-call transcripts are available for CALC yet.
- Free Float
- 109.8%
- Shares Outstanding
- 3.15M
- Float Shares
- 3.46M
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 407.80K | ▲ 31.18K |
| Meritage Portfolio Management | 61.54K | 0 |
| Sheets Smith Investment Management | 51.10K | ▲ 51.10K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Lawler Sean Patrick | other | 10,000 |
| Nov 10, 26 | Lawler Sean Patrick | other | 0 |
| Nov 10, 26 | Lawler Sean Patrick | other | 0 |
| Nov 10, 26 | Lawler Sean Patrick | other | 0 |
| Nov 10, 26 | Lawler Sean Patrick | other | 0 |
| Nov 10, 26 | Lawler Sean Patrick | other | 0 |
| Nov 10, 26 | Lawler Sean Patrick | other | 0 |
| Nov 10, 26 | Lawler Sean Patrick | other | 0 |
| Nov 10, 26 | Lawler Sean Patrick | other | 0 |
| Nov 10, 26 | Lawler Sean Patrick | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CALC coverage
Recent articles, reports, and earnings notes.
No research on CALC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CALC report →What Makes CalciMedica Inc. (CALC) a New Buy Stock
zacks.com · Nov 12
CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
globenewswire.com · Nov 10
CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
globenewswire.com · Nov 3
CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Price Target of $50.00 According to Analysts
defenseworld.net · Oct 12
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 8
CalciMedica Announces One-for-Five Reverse Stock Split
globenewswire.com · Aug 27
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
prnewswire.com · Jul 29
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
prnewswire.com · Jun 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.